Payment overview · 2025
General Payments
$563.93
24 reported records · 12 companies
Healthcare provider profile · identity verified
Michael L Sacher, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · MASSAPEQUA, NY · NPI 1831174473
Verified facts
What the public records show
CMS Open Payments records show Michael L Sacher, DO received $563.93 in general payments during 2025 across 24 reported records.
Abbott Laboratories accounted for 33.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nexlizet by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $187.54 | 33.3% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $66.95 | 11.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $43.76 | 7.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.38 | 7.5% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.51 | 7.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.54 | 6.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.68 | 5.4% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $30.23 | 5.4% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $24.16 | 4.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.28 | 3.8% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $20.87 | 3.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.03 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $563.93 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $89.06 | 4 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $76.22 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $66.95 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.38 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.54 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.54 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.54 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.68 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $30.23 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| MERLIN@HOME Normalized: merlin home |
Device | Abbott Laboratories | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $17.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 122 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 25 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
122 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 916 | 213 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 777 | 212 |
| Losartan Potassium | Losartan Potassium | 442 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 391 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 331 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 200 | 52 |
| Repatha Sureclick | Evolocumab | 142 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 39 |
| Xarelto | Rivaroxaban | 127 | 34 |
| Ezetimibe | Ezetimibe | 123 | 34 |
| Ozempic | Semaglutide | 122 | 20 |
| Furosemide | Furosemide | 120 | 38 |
| Eliquis | Apixaban | 116 | 25 |
| Ramipril | Ramipril | 111 | 28 |
| Alprazolam | Alprazolam | 102 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 92 | 27 |
| Jardiance | Empagliflozin | 89 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 89 | 22 |
| Carvedilol | Carvedilol | 88 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 14 |
| Metformin Hcl Er | Metformin Hcl | 75 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 28 |
| Omeprazole | Omeprazole | 67 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 16 |
| Mounjaro | Tirzepatide | 63 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 21 |
| Valsartan | Valsartan | 57 | 15 |
| Sertraline Hcl | Sertraline Hcl | 56 | 13 |
| Eszopiclone | Eszopiclone | 54 | suppressed |
| Metformin Hcl | Metformin Hcl | 54 | 14 |
| Lisinopril | Lisinopril | 51 | 15 |
| Entresto | Sacubitril/Valsartan | 48 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Simvastatin | Simvastatin | 42 | 13 |
| Synthroid | Levothyroxine Sodium | 41 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 12 |
| Famotidine | Famotidine | 39 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | 11 |
| Spironolactone | Spironolactone | 37 | 11 |
| Potassium Chloride | Potassium Chloride | 35 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Ranolazine Er | Ranolazine | 35 | suppressed |
| Praluent Pen | Alirocumab | 30 | suppressed |
| Azithromycin | Azithromycin | 26 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | 13 |
| Atenolol | Atenolol | 21 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 20 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Toprol Xl | Metoprolol Succinate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Gabapentin | Gabapentin | 15 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $563.93 · 24 records | Abbott Laboratories | ABRYSVO, ASSURITY, CAMZYOS, COMIRNATY, CONTRAVE, FARXIGA, JOT DX, Kerendia, LOKELMA, LifeVest, MERLIN@HOME, NEXLETOL, Ozempic, PREVNAR 20, REPATHA, SYMPLICITY G3, WATCHMAN FLX | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error